Portola Pharma (PTLA) Tops Q3 EPS by 19c

Portola Pharma (NASDAQ: PTLA) reported Q3 EPS of ($1.05), $0.19 better than the analyst estimate of ($1.24). Revenue for the quarter came in at $2.9 million versus the consensus estimate of $2.45 million.

For earnings history and earnings-related data on Portola Pharma (PTLA) click here.

You May Also Be Interested In

• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• Beike (BEKE) PT Raised to $23 at Morgan Stanley
• BMO starts chip stocks coverage: Here are its preferred picks